Overview

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.